These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 32320482)

  • 1. Using Healthcare Databases to Replicate Trial Findings for Supplemental Indications: Adalimumab in Patients with Ulcerative Colitis.
    Spoendlin J; Desai RJ; Franklin JM; Glynn RJ; Payne E; Schneeweiss S
    Clin Pharmacol Ther; 2020 Oct; 108(4):874-884. PubMed ID: 32320482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study.
    Singh S; Andersen NN; Andersson M; Loftus EV; Jess T
    Clin Gastroenterol Hepatol; 2017 Aug; 15(8):1218-1225.e7. PubMed ID: 27913244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Aliment Pharmacol Ther; 2016 May; 43(9):994-1003. PubMed ID: 26991059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Incidence of Suboptimal Response to Anti-Tumor Necrosis Factor Therapy for Ulcerative Colitis: A Nationwide Population-Based Study.
    Shin JY; Park HM; Lee MY; Jeon JY; Yoo HJ; Ye BD
    Gut Liver; 2021 Nov; 15(6):867-877. PubMed ID: 33785664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis.
    Lee YI; Park Y; Park SJ; Kim TI; Kim WH; Cheon JH
    Gut Liver; 2021 Mar; 15(2):232-242. PubMed ID: 32616683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneously Administered Anti-TNFs for the Treatment of Ulcerative Colitis: A Retrospective, Propensity Score-Matched, US Health Claims Analysis.
    Stewart MJ; Bessissow T; Gregor J; Hazel M; In TSH; Karra K; Dajnowiec D; Williamson M; Sattin B
    Adv Ther; 2021 Jul; 38(7):4115-4129. PubMed ID: 34159558
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.
    Sandborn WJ; Sakuraba A; Wang A; Macaulay D; Reichmann W; Wang S; Chao J; Skup M
    Curr Med Res Opin; 2016 Jul; 32(7):1233-41. PubMed ID: 26986449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
    Kobayashi T; Motoya S; Nakamura S; Yamamoto T; Nagahori M; Tanaka S; Hisamatsu T; Hirai F; Nakase H; Watanabe K; Matsumoto T; Tanaka M; Abe T; Suzuki Y; Watanabe M; Hibi T;
    Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):429-437. PubMed ID: 33887262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacies of first and second tumor necrosis factor inhibitors in refractory ulcerative colitis patients in real-world practice.
    Marutani Y; Mizoshita T; Sugiyama T; Togawa S; Katano T; Yamada T; Hirata Y; Kimura Y; Miyaki T; Inoue Y; Suzuki E; Sasaki M; Kataoka H
    Indian J Gastroenterol; 2020 Dec; 39(6):565-575. PubMed ID: 33106991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Long-Term Drug Survival of Vedolizumab, Adalimumab, and Infliximab in Biologic-Naïve Patients with Ulcerative Colitis.
    Dalal RS; McClure EL; Marcus J; Allegretti JR
    Dig Dis Sci; 2023 Jan; 68(1):223-232. PubMed ID: 35415826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Real-World Outcomes of Infliximab versus Adalimumab in Biologic-Naïve Korean Patients with Ulcerative Colitis: A Population-Based Study.
    Han M; Jung YS; Cheon JH; Park S
    Yonsei Med J; 2020 Jan; 61(1):48-55. PubMed ID: 31887799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy.
    Mizoshita T; Katano T; Tanida S; Hirano A; Miyaki T; Ozeki K; Suzuki Y; Sugimura N; Kataoka H; Joh T
    Medicine (Baltimore); 2017 Aug; 96(32):e7800. PubMed ID: 28796080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
    Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
    Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF therapy for ulcerative colitis in Brazil: a comparative real-world national retrospective multicentric study from the Brazilian study group of IBD (GEDIIB).
    Sassaki LY; Magro DO; Saad-Hossne R; Baima JP; Flores C; Correia LM; Celani LMS; De Abreu Ferrari ML; Zacharias P; Feitosa MR; Dos Santos CHM; De Freitas Lins Neto MA; Quaresma AB; De Lima Junior SF; De Vasconcelos GBS; Cassol OS; Dos Santos Pinto A; Kurachi G; Goncalves Filho FA; Gasparini RG; Furlan TK; Catapani WR; Coy CSR; De Souza Menegassi V; Colombo MM; Fróes RSB; Teixeira FV; Moraes AC; Santana GO; Parente JML; Vilela EG; Queiroz NSF; Kotze PG;
    BMC Gastroenterol; 2022 May; 22(1):268. PubMed ID: 35644668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis.
    Zhou Z; Dai C; Liu WX
    Hepatogastroenterology; 2015 Jun; 62(140):829-37. PubMed ID: 26902011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term real-life efficacy and safety of infliximab and adalimumab in the treatment of inflammatory bowel diseases outpatients.
    Tursi A; Mocci G; Lorenzetti R; Allegretta L; Brandimarte G; Cassieri C; Colucci R; De Medici A; Faggiani R; Ferronato A; Fiorella S; Forti G; Franceschi M; Gallina S; Giorgetti G; Grasso G; Larussa T; Luzza F; Penna A; Pica R; Piergallini S; Porciello S; Pranzo G; Rodino' S; Scorza S; Sebkova L; Zampaletta C; Elisei W; Picchio M
    Eur J Gastroenterol Hepatol; 2021 May; 33(5):670-679. PubMed ID: 33741797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
    Inokuchi T; Takahashi S; Hiraoka S; Toyokawa T; Takagi S; Takemoto K; Miyaike J; Fujimoto T; Higashi R; Morito Y; Nawa T; Suzuki S; Nishimura M; Inoue M; Kato J; Okada H
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emulation of a randomized controlled trial in ulcerative colitis with US and French claims data: Infliximab with thiopurines compared to infliximab monotherapy.
    Kirchgesner J; Desai RJ; Schneeweiss MC; Beaugerie L; Kim SC; Schneeweiss S
    Pharmacoepidemiol Drug Saf; 2022 Feb; 31(2):167-175. PubMed ID: 34498314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
    Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.